ScholarIQanswers from OpenAlex
Bordeaux Population Health
InstitutionResearch output, impact & collaborations
Bordeaux Population Health is a institution indexed in ScholarIQ from OpenAlex.
What is known about Bordeaux Population Health?
ScholarIQrecord summary
Bordeaux Population Health is a research organisation in Bordeaux, FR. OpenAlex records 15,458 works and 1,145,328 citations for it. 3,619 researchers list it as their most recent affiliation.
How many works does Bordeaux Population Health have?
ScholarIQindexed works
Bordeaux Population Health has 15,458 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Bordeaux Population Health have?
ScholarIQcitation count
Bordeaux Population Health has 1,145,328 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Bordeaux Population Health?
ScholarIQresearcher count
Bordeaux Population Health has 3,619 researchers in the ScholarIQ index.
What is the average h-index at Bordeaux Population Health?
ScholarIQavg h-index
Bordeaux Population Health has an average h-index of 80 in OpenAlex.
What is the ROR of Bordeaux Population Health?
ScholarIQror
The ROR for Bordeaux Population Health is on the source record.
What is the OpenAlex record for Bordeaux Population Health?
ScholarIQopenalex
The OpenAlex for Bordeaux Population Health is on the source record.
Who are the most-cited researchers behind Bordeaux Population Health?
ScholarIQtop researchers by citations
What are the most-cited papers on Bordeaux Population Health?
ScholarIQmost cited works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier
Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
David F. McDermott, Mahrukh Huseni, Michael B. Atkins, Robert J. Motzer, Brian I. Rini, Bernard Escudier, Lawrence Fong, Richard W. Joseph, Sumanta K. Pal, James A. Reeves, Mario Sznol, John D. Hainsworth, W. Kimryn Rathmell, Walter M. Stadler, Thomas E. Hutson, Martin Gore, Alain Ravaud, Sergio Bracarda, Cristina Suárez, Riccardo Danielli, Viktor Gruenwald, Toni K. Choueiri, Dorothee Nickles, Suchit Jhunjhunwala, Elisabeth Piault‐Louis, Alpa Thobhani, Jiaheng Qiu, Daniel S. Chen, Priti S. Hegde, Christina Schiff, Gregg Fine, Thomas Powles
Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
Arnaud Méjean, Alain Ravaud, Simon Thézenas, Sandra Colas, Jean‐Baptiste Beauval, Karim Bensalah, Lionnel Geoffrois, Antoine Thiery-Vuillemin, Luc Cormier, Hervé Lang, Laurent Guy, Gwénaëlle Gravis, Frédéric Rolland, Claude Linassier, É. Lechevallier, Christian Beisland, Michael Aitchison, Stéphane Oudard, Jean‐Jacques Patard, C Théodore, Christine Chevreau, Brigitte Laguerre, Jacques Hubert, Marine Gross‐Goupil, Jean‐Christophe Bernhard, Laurence Albigès, Marc‐Olivier Timsit, Thierry Lebrét, Bernard Escudier
How much of the research on Bordeaux Population Health is open access?
ScholarIQopen access share
75%OPEN ACCESS